Ziad2022-11-25T13:59:44-05:00CytoAgents primarily focuses on developing a single lead drug, coded CTO1681, in multiple indications involving cytokine release syndrome (CRS). Simply stated, CRS is “an overreaction of the immune system, commonly known as cytokine storm.” It has many causes and affects many areas and systems of the body. CTO1681 targets the NF-kB (nuclear factor kappa B) signaling pathway to modulate cytokine production, thus reducing inflammation. CytoAgents has early programs in four areas: oncology (with CAR T-cell therapy), dermatology (atopic dermatitis), neurology...